Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Investing Activities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash from Investing Activities over the past 16 years, most recently at -$2.1 million for Q2 2025.

  • Quarterly results put Cash from Investing Activities at -$2.1 million for Q2 2025, up 22.71% from a year ago — trailing twelve months through May 2025 was -$6.4 million (up 65.13% YoY), and the annual figure for FY2025 was -$6.4 million, up 65.13%.
  • Cash from Investing Activities for Q2 2025 was -$2.1 million at Lifecore Biomedical, Inc. \De\, down from $1.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for LFCR hit a ceiling of $65.2 million in Q1 2022 and a floor of -$17.5 million in Q2 2022.
  • Median Cash from Investing Activities over the past 5 years was -$3.1 million (2024), compared with a mean of $2.1 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 139607.41% in 2021 and later tumbled 2136.28% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities stood at -$5.4 million in 2021, then grew by 29.06% to -$3.8 million in 2022, then decreased by 10.73% to -$4.3 million in 2023, then skyrocketed by 42.74% to -$2.4 million in 2024, then grew by 14.06% to -$2.1 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$2.1 million (Q2 2025), $1.5 million (Q1 2025), and -$2.4 million (Q4 2024) per Business Quant data.